-
Dongbao to acquire Ferring’s Malmö manufacturing operation
in PRESS RELEASE 2006 onFerring Pharmaceuticals and Shanghai Dongbao Biopharmaceutical Company announced today the signing of an agreement by which Dongbao Biopharmaceutical will purchase Ferring’s manufacturing operation at Malmö in Sweden…
0 -
Symposium looks at potential of mesalazine to prevent colorectal cancer in IBD (14th United European Gastroenterology Week, 21-25 October 2006)
in PRESS RELEASE 2006 onSpeaking today at a Ferring-sponsored symposium on the occasion of the 14th United European Gastroenterology…
-
Ferring Pharmaceuticals Officially Opens Its Production Site and Global Administrative Headquarters
in PRESS RELEASE 2006 onFerring Pharmaceuticals, the pioneering Swiss pharmaceutical group and world leader in industrial synthesis of peptides, today officially opens its new production site and administrative Headquarters in Saint-Prex in the canton of Vaud…
-
Assisted Reproductive Technology helps address demographic challenge in Europe
in PRESS RELEASE 2006 onNew research conducted by the independent ‘think tank’ RAND Europe discusses one potential solution to the population ageing crisis in Europe that has not yet been considered…
-
Degarelix, a novel GnRH blocker from Ferring, moves into phase III
in PRESS RELEASE 2006 onFollowing the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous promising studies, Ferring Pharmaceuticals announced the immediate start of Phase III trials…
-
Ferring and Astellas enter a license agreement on Degarelix for the treatment of prostate cancer in Japan
in PRESS RELEASE 2006 onFerring Pharmaceuticals (“Ferring”; headquarters: Lausanne, Switzerland; executive chairman: Frederik Paulsen) and Astellas Pharma Inc….
PRESS RELEASE 2006
PRESS RELEASE 2006